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Abnormal norepinephrine uptake and release in brain
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Abnormal norepinephrine uptake and release in brain synaptosomes in
chronic renal failure. Abnormalities in the function of the central
nervous system exist in chronic renal failure (CRF) and some of these
derangements may be related to excess parathyroid hormone (PTH)
which causes a rise in brain calcium. The latter may affect metabolism
of neurotransmitters such as norepinephrine (NE) in brain synapto-
somes. We measured NE content, uptake and release in brain synap-
tosomes of CRF rats and studied whether excess PTH affects these
parameters. Synaptosomes from rats with 21 days of CRF compared to
those from normal animals have higher calcium content (11,4 0.92 vs.
7.1 0.50nmol/mg protein, P <0.01) and lower Na-K ATPase activity
(6.5 0.81 vs. 11.4 0.76 mol Pi/mg protein/hr, P < 0.01). NE
content (11.0 0.60 vs. 13.6 0.55 pmol/mg protein/hr. P < 0.01),
uptake (46 4.5 vs. 110 5.9 pmol/mg protein times 50 mm, P <0.01)
and release (2.0 0.2 vs. 5.1 0.47 pmol/mg protein times 10 mm, P
< 0.01). Parathyroidectomy (PTX) in CRF rats kept normocalcemic
reversed these abnormalities in brain synaptosomes; indeed calcium
content, Na-K ATPase activity and NE content, uptake and release in
synaptosomes from PTX-CRF rats were not different from those seen in
normal rats. Administration of 1-84 PTH for 21 days produced abnor-
malities in brain synaptosomes similar to those seen in CRF rats; the
synaptosomes from PTH-treated animals had significantly (P < 0.01)
higher calcium content (10.0 0.80 nmol/mg protein) and lower Na-K
ATPase activity (8.3 0,58 tmol Pilmg protein/hr), and NE content
(8.8 0.51 pmol/mg protein), uptake (87 4.0 pmol/mg protein times
50 mm) and release (2.3 0.27 pmol/mg protein times 10 mm).
However, in PTH-treated animals the initial rate of NE uptake was not
different from normal but the steady state rate was reduced. In contrast,
both the initial and steady state NE uptake were significantly reduced in
CRF control rats. Despite this greater effect of CRF on NE uptake, the
decrease in NE content in the synaptosomes of CRF control rats was
significantly less than that in PTH-treated animals. The data show that
abnormalities in the function of synaptosomes occur in CRF and they
are most likely due in large part to excess PTH. The latter may act
directly and/or mediate its effect through accumulation of calcium in the
synaptosomes. Other factors associated with CRF or administration of
PTH may also contribute to some of these abnormalities in synapto-
somes function.
Previous studies have demonstrated that parathyroid hor-
mone (PTH) may act as a neurotoxin when its blood levels are
elevated [1—4]. This effect was attributed to the ability of the
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hormone to enhance movement of calcium into cells [5—71
causing an increase in the calcium content of the brain [8—111.
Indeed, in acute and chronic renal failure, which are states
associated with secondary hyperparathyroidism [11—141, cal-
cium content of brain is increased and distinct abnormalities are
noted in the electroencephalogram (EEG) [10, 11, 15, 16j.
Parathyroidectomy or medical suppression of the parathyroid
gland activity is followed either by marked improvement in, or
reversal of, these changes in brain calcium and EEG [3, 8, 10,
11, 15, 16]. The mechanisms underlying the effects of the
increase in brain calcium and/or excess PTH, per Se, on brain
function are not known.
It is well established that changes in the concentration or
metabolism of cerebral catecholamines, which are neurotrans-
mitters, can modify both somatic and behavioral patterns. It has
been shown that the release of neurotransmitters in the synaptic
space of the nerve terminals in brain is partly calcium depen-
dent and partly carrier-mediated [17—20].
It is theoretically possible that the effect of excess PTH on
brain calcium also includes changes in calcium metabolism of
brain synaptosomes. Indeed, Fraser, Sarnacki and Arieff [21,
22] have demonstrated that PTH enhances Na-Ca exchange and
the ATP-dependent calcium transport by brain synaptosomes
[22], and this action may be responsible for the accumulation of
calcium in brain synaptosomes in acute uremia [21). This effect
of PTH on calcium synaptosomes may influence the release of
neurotransmitters such as norepinephrine (NE) from these
structures.
NE uptake by brain synaptosomes is dependent on sodium
gradient [23] and is influenced by the Na-K ATPase activity of
these structures [24—26]. Certain data suggest that Na-K
ATPase activity of brain or brain synaptosomes obtained from
animals with acute uremia is impaired [27, 28]. It is possible that
this abnormality is related to the state of secondary hyperpara-
thyroidism of uremia, and therefore, excess PTH in renal failure
may affect NE uptake by brain synaptosomes. Finally, an effect
of PTH on NE release and/or uptake may alter NE content of
brain synaptosomes.
The present study was undertaken to examine the effect of
PTH and of chronic renal failure with and without excess PTH
on NE uptake and release by brain synaptosomes and on their
NE content.
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Methods
Male Sprague-Dawley rats weighing 275 to 320 g were stud-
ied. The animals were fed normal rat chow (ICN Nutritional
Biochemical, Cleveland, Ohio, USA) throughout the study.
One group of rats received intraperitoneal injection of 150
U/day of 1-84 PTH (Sigma Chemical Co., St. Louis, Missouri,
USA) for 21 days. The hormone was dissolved in normal saline,
and half of the daily dose was given in the morning and the other
half in the late afternoon hours. The control animals received
sham injections of vehicle (saline) only.
Studies were also performed after 21 days of chronic renal
failure in the presence and absence of the parathyroid glands.
Parathyroidectomy (PTX) was done by electrocautery, and the
success of the procedure was ascertained by a decrease in
plasma levels of calcium of at least 2 mg/dl. The mean value of
plasma calcium for the six PTX rats that were included in the
study fell from 9.95 0.08 to 7.60 0.11 mg/dl after parathy-
roidectomy. The PTX rats were allowed to freely drink water
containing 50 g/liter of calcium gluconate. This procedure is
adequate to normalize plasma calcium in PTX rats. Seven days
after PTX, the animals underwent right partial nephrectomy
through a flank incision; a week later, a left nephrectomy was
performed. The nephrectomy procedures were also performed
in rats with intact parathyroid glands. Thus, this protocol
provided two groups of animals with chronic renal failure
(CRF): one with intact parathyroid glands (CRF control) and
the other without parathyroid glands (CRF-PTX).
All rats were sacrificed at day 22 of the study by decapitation.
Blood was collected in heparinized tubes for the measurements
of creatinine, calcium and phosphorus. The forebrains of the
animals were immediately removed, placed in ice-cold (4°C)
isolation media (320 m sucrose, 0.2 m'vi K-EDTA, 5 mM
Tris-HC1, pH 7.4) and chopped into small pieces with scissors.
The chopped tissues were washed three times with isolation
media. Synaptosomes were prepared according to the method
of Booth and Clark [291 with minor modifications. One brain
was used for each synaptosomes preparation. The chopped
tissues were homogenized in a Dounce-type glass homogenizer
by 12 up and down strokes with a glass pestile (total clearance
0.1 gm). The homogenate was diluted to 15 ml with isolation
media and spun at 1300 g for three minutes with Sorval RC-5
refrigerated centrifuge (4°C) (DuPont Co., Instrument Product
Division, Newton, Connecticut, USA). The supernatant from
this spin was centrifuged at 17000 g for 10 minutes, producing
the crude mitochondrial/synaptosomes pellet. The latter was
resuspended to 9 ml with 12% Ficoll/sucrose medium (12%
W/W Ficoll, 320 m sucrose, 0.2 mrvi K-EDTA, 5 mrvi Tris-HCI,
pH 7.4) and gently homogenized in a Thomas glass-Teflon
homogenizer (clearance 0.004 to 0.006 inch). This crude prep-
aration was placed into a centrifuge tube and above it 9 ml of
7.5% Ficoll/sucrose medium was carefully layered, and on top
of this 9 ml of isolation medium was layered. The tubes were
centrifuged at 100,000 g for 30 minutes with a Beckman ultra-
centrifuge (Model L5-50, SW-28 rotor, Beckman Instruments
Inc., Palo Alto, California, USA). At the completion of the
spin, the purified synaptosomes were located at the interface
between the 12 and 7.5% Ficoll layers. The synaptosomes were
carefully removed by suction with a plastic disposable pipette
and the pellet was brought up to 15 ml with ice-cold isolation
medium and homogenized again in a Thomas glass-Teflon
homogenizer. The homogenate was then centrifuged at 17000 g
for 10 minutes with Sorval RC-5 refrigerated centrifuge. The
supernatant was discarded and the pellet was resuspended in
1.5 to 2.0 ml of isolation medium to achieve a concentration of
proteins of 7 to 10 mg/ml. The synaptosomal suspension was
divided and placed in five test tubes, frozen with liquid nitrogen
and stored at —70°C. At a later date the synaptosomes were
thawed for the study of NE content, uptake and release,
calcium content and Na-K ATPase activity.
We used various approaches to evaluate the intactness of the
synaptosomes in our preparation, their viability and the degree
of contamination with mitochondria and endoplasmic reticu-
lum. Figure 1 shows an electron micrograph of the synaptoso-
mal preparation demonstrating the intactness of the membrane
of the synaptosomes and of their mitochondria and vesicles and
of the synaptic cleft. Oxygen consumption at stage 3 by the
synaptosomes was studied polarographically by means of a
Clark oxygen electrode (Gilson Medical Electronics, Middel-
ton, Wisconsin, USA) fitted to a plexiglass chamber of 2.0 ml
capacity as described originally by Chance and Williams [30].
The oxygraph medium contained 100 mM NaCI, 75 mM manni-
tol, 25 mivi sucrose, 10 mrvi Tris phosphate, 10 mM Tris HCI and
0.05 mM K-EDTA with a pH 7.4. The substrates used were a-
ketoglutarate and pyruvate. These studies showed values of
oxygen consumption of 7.8 0.86 mol O2/mg protein per mm
with a-ketoglutarate and of 6.5 0.45 mol 02/mg protein per
mm with pyruvate. These values are within the range previ-
ously described by others [29] and indicate that they are
metabolically competent. Lactic dehydrogenase was measured
with and without 0.5% Triton and the reaction was carried out
at 30°C [31). The values were 253 19 nmollmg protein per mm
without Triton and 973 88 nmol/mg protein per mm with
Triton, indicating intactness of the synaptosomes. Rotenon-
insensitive NADH and NADPH cytochrome c reductase were
determined by the method of Duncan and Mackler [32] at 30°C
and a wavelength of 550 nm using a Beckman spectrophotom-
eter (Model 25, Beckman Instruments Inc., Palo Alto, Califor-
nia, USA). The reaction mixture consisted of 1.45 ml of 0.3 mM
KCN, 0.10 mivi NADPH, 0.1 mrvi cytochrome c and 1.5 mM
rotenon and 50 mi Tris buffer (pH 7.4) to which 0.05 ml of
synaptosomes was added. NADH and NADPH cytochrome c
reductase activities were 4.3 0.25 and 1.1 0.06 nmollmg
protein per mm, respectively. The calculated mitochondrial
contamination of the synaptosomal preparation was 7.6
0.64%.
NE content of brain synaptosomes was determined by radio-
enzymatic method described by DaPrada and Zurcher [33), and
the data are expressed in pmol/mg protein. The uptake of
3H-NE was measured by a modification of the method of
Pastuszko, Wilson and Erecinska [341. The synaptosomes prep-
aration was thawed at 30°C for five minutes, centrifuged at 1200
g for 10 minutes and the pellet resuspended in a modified
Krebs-Henseleit-HEPES buffer (140 m'vi NaC1, 5 mM KCI, 1.3
mM MgSO4, 5 mM NaHCO3, 1.3 m'vi CaCI2, 1 mM Tris
phosphate, 10 mrvi HEPES, pH 7.4) containing 10 m glucose.
One tenth ml of the synaptosomes suspension was added to 1.7
ml of the buffer and pre incubated for six minutes at 30°C. At the
end of the preincubation, 66 pmols of DL-3H NE hydrochloride
(Amersham International, United Kingdom; specific activity 15
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Cilmmol of NE) was added. Aliquots of 200 jsl were then
withdrawn at 0, 1, 3, 5, 10, 15, 20, 30, 40 and 50 minutes and
rapidly centrifuged (Beckman microfuge, Beckman Instruments
Inc.) through a layer of silicone oil (specific gravity 1.025 to
1.030, General Electric, Waterford, New York, USA). Radio-
activity in the supernatant and in the pellet was measured with
a Beckman LS-7000 liquid scintillation counter (Beckman In-
struments Inc.) using Amersham aqueous scintillant. The radio-
activity accumulated in the pellet at each time point was
calculated as a percent of total radioactivity added initially to
the mixture. The value obtained at time 0 was considered to
reflect nonspecific binding and was subtracted from the values
at the various time points; this allowed the estimation of NE
uptake which is expressed as pmollmg protein.
NE release from brain synaptosomes was measured by the
method of Pastuszko et al [34]. The synaptosomes preparation
was thawed, centrifuged and the pellet resuspended in a mod-
ified Krebs-Henseleit-HEPES buffer containing glucose as de-
scribed above. Two tenth ml of the synaptosomes preparation
was added to 1.7 ml of the buffer which was kept at 37°C, and
132 pmol of DL-3H NE hydrochloride in 100 d was added to
the suspension and the mixture was incubated for 20 minutes at
37°C. The tube was then placed in ice for five minutes to rapidly
cool the synaptosomes preparation. It was then centrifuged at
17000 g for 10 minutes. The supernatant was removed and the
pellet was resuspended in 1 ml of high potassium (70 mM KCI)
Kreb-Henseleit-HEPES buffer. Aliquots of 200 l were with-
Fig. 2. Norepinephrine content ofbrain synaptosomes in the various
groups of animals studied. Each column represents the mean values
and the bracket denotes I SE. There were 12 studies in normal and CRF
control and 6 studies in CRF-PTX and 1-84 PTH treated animals.
drawn at 0, 1, 3. 5 and 10 minutes and rapidly centrifuged with
Beckman microfuge through silicone oil. Radioactivity in the
supernatant and pellet was measured by a Beckman spectro-
photometer LS-7000 liquid scintillation. The radioactivity in the
Fig. I. An electron micrograph of a section of the 3ynapiosomal peilci I' 2 Ith)O).
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pelletat 0 time would reflect the degree of loading with 3H NE.
The radioactivity in the supernate is a function of the release of
3H NE from the synaptosomes over time.
The activity of synaptosomal Na-K ATPase was estimated by
measuring the hydrolysis of ATP (4 mM) in two buffered media
[351. The first medium contained 150 mii NaCI, 5 mivi MgCI2, 50
mM Tris HCI, 1 mivi EDTA, pH 7.4, but no potassium; this
medium was considered a "blank" since Na-K ATPase is
inactive in it. The second medium is similar to the first except it
contained 10 mrvi KCI. One tenth ml of the synaptosomes
suspension was added to 0.8 ml of each of the two media, and
the mixtures were preincubated for five minutes at 37°C; 0.1 ml
of ATP Tris buffer was then added, and the mixture was
incubated for 10 minutes at 37°C. The reaction was stopped by
0.25 ml of ice-cold 10% trichloroacetic acid and the solution was
centrifuged at 3300 g for 10 minutes to remove protein. Inor-
ganic phosphorus was measured in supernatarit, and the differ-
ence in inorganic phosphorus between media with and without
KCI was calculated. ATPase activity was expressed in xmol
Pi/mg protein/hour.
The measurements of calcium in synaptosomes were made by
the method of Goldfarb and Rod night [361 for the measurement
of calcium in membrane fragments of cerebral cortex, These
authors reported a value for calcium from normal rats of 8 1
nmol/mg protein, which is not different from our observations in
normal synaptosome (7.1 0.5 nmol/mg protein).
Calcium content of synaptosome and calcium concentration
in plasma were determined by Perkin Elmer spectrophotome-
ter, model 505 (Perkin Elmer Corporation, Norwalk, Connect-
icut, USA). Inorganic phosphorus and creatinine were mea-
sured with an autoanalyzer (Technicon Corp. Tarrytown, New
York, USA). Changes in parameters with multiple measure-
ments over time were evaluated by calculating area under the
curve for each experiment. Data are expressed as mean SE
and statistical significance was evaluated by parametric t-test.
Results
The results are presented in Table I and Figures 2 through 6.
The treatment of rats for 21 days with 1-84 PTH did not cause
a significant rise in the plasma levels of calcium but was
associated with a significant (P < 0.01) reduction in plasma
levels of inorganic phosphorus; there were no significant
changes in the blood levels of creatinine after PTH injection and
the values were not different from control rats (Table 1).
The administration of 1-84 PTH was associated with a signif-
icant (P < 0.01) reduction in NE content of synaptosomes (8.8
0.51 pmol/mg protein) as compared to control values (13.6
0.55 pmol/mg protein), Figure 2. PTH treatment also caused a
significant reduction in NE uptake by (area under the curve of
110 5.9 pmol/mg protein times 50 mm in normal and 87 4.0
pmol/mg protein times 50 mm in PTH-treated animals, P <
0.01, Fig. 3) and NE release from (area under the curve of 5.1
0.47 pmol/mg protein times 10 mm in normal and 2.3 0.27
pmol/mg protein times 10 mm in PTH-treated rats, P < 0.01,
Fig. 4) brain synaptosomes. The initial rate of NE uptake (1 to
15 minutes) was not affected by PTH treatment but the steady-
state NE uptake (20 to 50 mm) was significantly reduced.
The activity of Na-K ATPase in the synaptosomes obtained
from PTH-treated rats (8.3 0.58 tmol Pi/mg protein/hr) was
significantly (P <0.01) lower than that of control animals (11.4
0.74 mol Pi/mg protein/hr), Figure 5. The calcium content of
the synaptosomes (10.0 0.80 nmol/mg protein) in rats receiv-
ing PTH was significantly (P < 0.01) higher than values of
control animals (7.1 0.50 nmol/mg protein), Figure 6.
The nephrectomy procedure resulted in a significant (P <
0.01) rise in the plasma levels of creatinine with the values being
three times higher than normal (Table 1). There were no
significant differences between the plasma levels of calcium and
phosphorus in CRF control and CRF-PTX rats, and the values
3
2
Smogorzewski et al: CRF, PTH and NE of synaptosomes 461
Fig. 3. Norepinephrine uptake by brain
synaptosomes obtainedfrom 6 normal (•), 8
CRF control (0), 6 CRF-PTX (s), and six
1-84 PTH (A) treated animals. Each data
point represents the mean value the bracket
denotes 1 SE.
0 135 10 20 30 40 50
Time, minutes
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CRF CRF-PTX 1-84 PTH
control
Fig. 5. Na-K A TPase activity ofbrain synaptosomes in various groups
of animals studied. Each column represents the mean value and the
bracket denotes 1 SE. There were 9 studies in normal and 6 studies in the
other groups of rats.
were not different from those in normal animals except for a
lower plasma phosphorus in CRF-PTX rats.
NE content in synaptosomes of CRF control rats (11.0 0.60
pmol/mg protein) was significantly lower (P < 0.01) than in
control animals (13.6 0.55 pmollmg protein) or in CRF-PTX
rats (14.8 1.02 pmol/mg protein), Figure 2. However, the
decrease in NE content in CRF control rats was significantly
less than in PTH-treated animals. There was no significant
difference between NE content of synaptosomes from CRF-
PTX and normal rats. NE uptake by brain synaptosomes from
CRF control rats (area under the curve of 46 4.5 pmol/mg
protein times 50 mm) was significantly (P < 0.01) lower than
that in control (area under the curve of 110 5.9 pmol/mg
protein times 50 mm) or CRF-PTX (area under the curve 107
2.9 pmollmg protein times 50 mm) rats (Fig. 3). In contrast to
12'
ml
Normal CRF CRF-PTX 1-84 PTH
control
PTH-treated rats, both the initial and the steady-state NE
uptake in CRF control rats was significantly reduced. The NE
uptake by synaptosomes from CRF-PTX animals was not
different from that in normal rats. NE release from brain
synaptosomes obtained from CRF control rats (area under the
curve of 2.0 0.20 pmol/mg protein times 10 mm) was
significantly (P < 0.01) lower than that in normal animals (area
under the curve of 5.1 0.47 pmol/mg protein times 10 mm) or
CRF-PTX (area under the curve of 4.3 0.57 pmollmg protein
times 10 mm) rats (Fig. 4). There was no significant difference in
NE release between control and CRF-PTX rats.
The Na-K ATPase activity in the synaptosomes from CRF
control animals (6.5 0.81 zmol Pi/mg protein/hr) was signif-
icantly (P < 0.01) lower than in control rats (11,4 0.76 mol
Pi/mg protein/hr), Figure 5. There was no significant difference
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Fig. 4. Norepinephrine release from brain
synaptosomes obtained from 6 normal (•), 8
CRF-control (0), 6 CRF-PTX (Lx), andsix
1-84 PTH (A) treated animals. Each data
point represents the mean values and the
bracket denotes 1 SE.
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Fig. 6. Calcium content of brain synaptosomes in the various groups
of animals studied. Each column represents the mean of 6 studies and
the bracket denotes I SE.
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Table 1. Body weight and blood chemistry in various groups of rats
Body weight
g
PLASMA mg/d!
Creatinine Calcium Phosphorus
Control 288 12 0.52 0.02 10.0 0.10 7.6 0.4
N = 12
1-84 PTH 300 5 0.64 0.02 9.7 0.20 5.8 0.4kN=6
CRF control 294 9 1.62 0.24a 9.4 0.40 6.8 0.4
N = 12
CRF-PTX 302 9 1.49 0.09a 10.2 0.26 5.8 0.6k
N= 6
Data are expressed as mean SE.
a P < 0.01 from control
between the Na-K ATPase activity of the synaptosomes from
normal rats and CRF-PTX animals.
The calcium content of synaptosomes from CRF control
animals (11.4 0.92 nmol/mg protein) was significantly higher
than that in normal rats (7.1 0.50 nmol/mg protein) or in
CRF-PTX animals (8.0 0.62 nmol/mg protein; Fig. 6), and
there was no significant difference in the calcium content
between the latter two groups.
Discussion
The results of the present study demonstrate that CRF exerts
a variety of effects on norepinephrine metabolism of brain
synaptosomes. CRF inhibits NE uptake and release by these
structures and is associated with a decrease in their NE
content. Two lines of evidence in our data indicate that these
effects are related to the state of secondary hyperparathyroid-
ism of CRF. First, parathyroidectomy in CRF rats prevented
these derangements in NE metabolism in brain synaptosomes.
Indeed, the values of NE uptake and release by brain synapto-
somes and their NE content in CRF-PTX rats were not different
from those in normal animals. Second, treatment of rats with
normal renal function with 1-84 PTH produced abnormalities in
NE metabolism of brain synaptosomes similar to those ob-
served in CRF rats. Thus, it is apparent that the changes in NE
metabolism of brain synaptosomes occur in animals with excess
PTH whether renal failure is present or not.
Our observations that the calcium content of brain synapto-
somes in CRF control rats and in 1-84 PTH treated animals is
elevated but is normal in CRF-PTX rats indicate that chronic
exposure to excess PTH is associated with accumulation of
calcium in brain synaptosomes. These data are in agreement
with the reports of Fraser, Sarnacki and Arieff [22] that PTH
enhances uptake of calcium by brain synaptosomes and that
this effect is responsible for the augmented calcium influx in
synaptosomes of rats with acute uremia [211. This accumulation
of calcium in brain synaptosomes may contribute to the de-
rangements in NE metabolism of these structures.
Our data on NE release and uptake in all groups of animals
are made of an initial phase, which most likely represents
undirectional fluxes followed by a sustained phase which de-
notes net influx (uptake) or efflux (release). The evaluation of
the slopes of the initial phases of NE uptake and release
requires frequent measurements during the first two minutes.
Such measurements were not made in our studies. Therefore,
the results of NE uptake and release are presented as area
under the curve which provides in large part the net influx or
efflux, respectively, during the period of time of the study.
NE release by brain synaptosomes is regulated in part by
calcium [17—201. An increase in calcium influx in brain synap-
tosomes is associated with an increase in NE release [20].
Theoretically, one would expect that PTH, a hormone able to
enhance calcium entry into cells, should stimulate rather than
inhibit NE release. However, it is possible that chronic expo-
sure to PTH and the associated chronic accumulation of cal-
cium exert an inhibitory effect on NE release. Indeed, NE
release was normal in CRF-PTX rats when calcium content of
synaptosomes was also normal. A corollary to this phenomenon
is found in the effects of PTH on other systems. A stimulatory
effect of acute exposure to the PTH and an inhibitory action
with chronic exposure to the hormone have been noted in the
heart [37—39] and leukocytes [40].
Previous studies have shown that acute renal failure is
associated with decreased activity of Na-K ATPase of brain and
brain synaptosomes [27, 28]. Our data extend these observa-
tions and demonstrate that chronic renal failure is also associ-
ated with reduced activity of Na-K ATPase. Since parathyroid-
ectomy prevented the reduction in Na-K ATPase activity of
brain synaptosomes from CRF rats and since treatment of rats
with normal renal function with PTH produced a significant
decrease in Na-K ATPase of brain synaptosomes, one can
suggest that the changes in Na-K ATPase activity is related to
the state of secondary hyperparathyroidism and not to other
consequences of CRF. It is possible that the effect of Na-K
ATPase is due either to a direct effect of the chronic state of
hyperparathyroidism or to the accumulation of calcium in brain
synaptosomes induced by the chronic exposure to excess PTH
or both.
The uptake of NE by brain synaptosomes requires energy
and is dependent, directly or indirectly, on Na-K ATPase
activity [24, 25]. Indeed, NE uptake is inhibited by ouabain [40,
41]. It is reasonable, therefore, to suggest that the decrease in
NE uptake by brain synaptosomes in CRF control rats and in
1-84 PTH treated animals may be due to the reduced Na-K
ATPase activity [42].
It should be mentioned that the effect of PTH treatment of
normal animals and that of CRF in animals with intact parathy-
roid glands on NE uptake by brain synaptosomes were dif-
ferent. PTH treatment was associated with a reduction in
steady state NE uptake only while CRF caused a reduction in
both the initial and the steady state rate of NE uptake. This
difference occurred in the face of significantly lower activity of
Na-K ATPase in the synaptosomes of CRF-control animals
than in PTH-treated rats, but with no significant difference in
calcium content. These observations suggest that other factors
in CRF besides excess PTH and/or calcium accumulation in
synaptosomes may also cause inhibition of Na-K ATPase.
The demonstration in our study of reduced NE content in
brain synaptosomes is in agreement with a previous report
showing a decrease in NE content in brain of rats with chronic
renal failure [43]. A reduction in NE content of brain synapto-
somes may be explained by alterations in NE uptake and
release. Such an explanation would require the assumption that
the inhibition in NE uptake is more marked than the inhibition
of NE release. However, one cannot delineate the mechanisms
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responsible for alterations in NE content of synaptosomes
without knowledge of their NE production. The processes
regulating NE production are complex and may be coupled with
NE release and be affected by calcium [44]. It is possible that
excess PTH and/or calcium accumulation in brain synapto-
somes affect NE production either directly and/or through their
influence on NE release. A reduction in the activity of tyrosine
hydroxylase, a rate limiting step in NE production, may also
produce a decrease in NE content. Data on the effect of PTH on
the activity of this enzyme are not available. It should be
mentioned, however, that Hennemann et al [45] reported that
the activity of tyrosine hydroxylase is reduced in brain slices of
rats with acute uremia. This change could have been due to the
state of secondary hyperparathyroidism of acute uremia.
It should be mentioned that NE content in synaptosomes
from PTH-treated rats was lower than that in CRF control
animals despite a greater inhibition in NE uptake in the latter
than the former groups of animals and a similar inhibition of NE
release. These observations suggest that other factor(s) may
also affect NE content in the PTH-treated animals. These
animals may have higher blood levels of I ,25(OH)2D since PTH
stimulates the production of this vitamin D metabolites [46, 47].
It is, theoretically, possible that such an excess in l,25(OH)2D
may affect NE content of brain synaptosomes by affecting its
synthesis.
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